A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-01

Study Completion Date

2020-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In December 2019, a group of patients with pneumonia of unknown cause was linked to a wholesale seafood market in Wuhan, China. The genetic analysis of samples from the lower respiratory tract of these patients indicated a new coronavirus as the causative agent, which was named SARS-CoV-2. The virus spread rapidly to more than 45 countries, including Brazil, causing an international alarm. However, in spite of its epidemiological magnitude, so far, there is no antiviral treatment or vaccine approved for the treatment of this infection. With about 15% to 20% of SARS-CoV-2 patients suffering from serious illnesses and overburdened hospitals, therapeutic options are desperately needed. So, instead of creating compounds from scratch that can take years to develop and test, researchers and public health agencies have sought to redirect drugs already approved for other diseases and known to be widely safe. In this context, the analysis of the international literature shows the existence of an in vitro antiviral activity of ivermectin against SARS-CoV-2. However, there are no studies that have evaluated its clinical effectiveness in patients diagnosed with SARS-CoV-2 infection. Therefore, and considering this knowledge gap, the present study aims to determine the clinical efficacy and safety of different doses of ivermectin in patients diagnosed with SARS-CoV-2 infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19

NCT04429711

COVID-19

UNKNOWN NA

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

NCT04407507

COVID-19

COMPLETED PHASE2

Ivermectin in Adults With Severe COVID-19.

NCT04602507

Covid19 Severe Acute Respiratory Syndrome

TERMINATED PHASE2

Efficacy of Ivermectin in Outpatients With Non-severe COVID-19

NCT04834115

Covid19 Coronavirus Infection

UNKNOWN PHASE3

COVidIVERmectin: Ivermectin for Treatment of Covid-19

NCT04438850

Covid19

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard of care

Standard of care (SOC) treatment

Standard treatment for COVID-19

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of infection by SARS-CoV-2:

1. symptoms of acute respiratory tract infection (sudden onset of at least one of the following: cough, fever, shortness of breath) and biomolecular diagnosis of SARS-CoV-2 infection; OR
2. any acute respiratory disease AND biomolecular diagnosis of SARS-CoV-2 infection; OR
3. severe acute respiratory infection (fever and at least one sign / symptom of respiratory disease eg cough, fever, shortness of breath) AND in need of hospitalization AND biomolecular diagnosis of SARS-CoV-2 infection;
* Eastern Cooperative Oncology Group Performance Status score 0 to 1;
* National Early Warning Score 0 to 4;
* Ability to understand and consent to participate in this clinical trial, manifested by signing the Informed Consent Form (ICF).

Exclusion Criteria

* Inability to ingest / absorb the study drug orally through spontaneous ingestion or use of gastro / enteral tubes;
* Any finding of clinical observation (history / physical evaluation) that is interpreted by the investigating physician as a risk to participate in the trial;
* Any laboratory test findings that the investigating physician considers as a risk to the research participant as to his / her participation in the clinical study;
* Any ECG examination finding that the investigating physician considers as a risk to the research participant as to his / her participation in the trial;
* Known hypersensitivity to the components of the drugs used during the study;
* Women in pregnancy or breastfeeding;
* Body weight less than 15kg;
* Estimated glomerular filtration rate (CKD-Epidemiology Collaboration, CKD-EPI) \<30 mL / min;
* Aspartate aminotransaminase (AST) or alanine aminotransaminase (ALT)\> 5 times the upper limit of normality;
* Refusal to participate;
* Refusal to sign the informed consent form.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No